California Public Employees Retirement System Assembly Biosciences, Inc. Transaction History

California Public Employees Retirement System

$141 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$3.8 - $4.56 $237,120 - $284,544	-62,400 Closed	0 $0
Q4 2020 Feb 02, 2021	SELL	$4.87 - $17.29 $34,552 - $122,672	-7,095 Reduced 10.21%	62,400 $378,000
Q3 2020 Nov 05, 2020	BUY	$15.08 - $27.04 $24,128 - $43,264	1,600 Added 2.36%	69,495 $1.14 Million
Q2 2020 Aug 12, 2020	BUY	$14.57 - $23.96 $290,744 - $478,121	19,955 Added 41.62%	67,895 $1.58 Million
Q1 2020 May 12, 2020	BUY	$10.27 - $21.23 $96,538 - $199,562	9,400 Added 24.39%	47,940 $711,000

Q4 2019 Jan 27, 2020	BUY	$8.36 - $23.81 $224,047 - $638,108	26,800 Added 228.28%	38,540 $789,000
Q2 2019 Aug 15, 2019	BUY	$12.9 - $20.8 $151,446 - $244,192	11,740 New	11,740 $158,000
Q1 2019 May 03, 2019	SELL	$17.7 - $24.93 $170,628 - $240,325	-9,640 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$19.05 - $36.45 $71,437 - $136,687	-3,750 Reduced 28.01%	9,640 $218,000
Q3 2018 Nov 13, 2018	BUY	$34.41 - $44.23 $21,024 - $27,024	611 Added 4.78%	13,390 $497,000
Q2 2018 Aug 15, 2018	SELL	$39.21 - $50.29 $418,096 - $536,242	-10,663 Reduced 45.49%	12,779 $501,000
Q1 2018 May 11, 2018	SELL	$41.7 - $64.16 $207,499 - $319,260	-4,976 Reduced 17.51%	23,442 $1.15 Million
Q4 2017 Feb 06, 2018	BUY	$28.58 - $49.91 $14,089 - $24,605	493 Added 1.77%	28,418 $1.29 Million
Q3 2017 Nov 15, 2017	BUY	$23.08 - $34.92 $644,509 - $975,141	27,925	27,925 $975,000

Others Institutions Holding ASMB

# of Institutions

Shares Held

16.3K

Call Options Held

Put Options Held

ETF Managers Group, LLC Summit, NJ

16.3K
Shares

$217,805
0.0% of portfolio

View Full List

About ASSEMBLY BIOSCIENCES, INC.

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $647M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

More about ASMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account